Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AtriCure (ATRC) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for AtriCure (ATRC) over the last 17 years, with Q3 2025 value amounting to $6.0 million.

  • AtriCure's Cash from Financing Activities rose 189699.7% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $816000.0, marking a year-over-year increase of 12736.42%. This contributed to the annual value of -$3.6 million for FY2024, which is 1115937.5% down from last year.
  • Per AtriCure's latest filing, its Cash from Financing Activities stood at $6.0 million for Q3 2025, which was up 189699.7% from $3.4 million recorded in Q2 2025.
  • AtriCure's Cash from Financing Activities' 5-year high stood at $6.0 million during Q3 2025, with a 5-year trough of -$10.7 million in Q1 2021.
  • Over the past 5 years, AtriCure's median Cash from Financing Activities value was $1.7 million (recorded in 2024), while the average stood at -$1.0 million.
  • In the last 5 years, AtriCure's Cash from Financing Activities plummeted by 65083.06% in 2021 and then soared by 189699.7% in 2025.
  • Quarter analysis of 5 years shows AtriCure's Cash from Financing Activities stood at $2.5 million in 2021, then dropped by 20.94% to $2.0 million in 2022, then increased by 19.02% to $2.4 million in 2023, then decreased by 26.32% to $1.7 million in 2024, then skyrocketed by 244.3% to $6.0 million in 2025.
  • Its Cash from Financing Activities was $6.0 million in Q3 2025, compared to $3.4 million in Q2 2025 and -$10.3 million in Q1 2025.